Clinical trials: Drug Induced Liver Injury
Drug-Induced Liver Injury
A Retrospective Study on Drug Induced Liver Injury in China
This is a multi-center, open-enrollment, retrospective, non-interventional epidemiologic study without any clinical treatment. Its primary objective is to understand 1) incidence of drug-induced liver injury, including incidences…
- Trial name
- DILI-R (NCT02407964)
- Where
- 371 sites in China
- Volunteers
- 15,000 people
- Sponsor
- Drug Induced Liver Disease Study Group
Acute Liver Failure, Acute Liver Injury
Safety Study of Ornithine Phenylacetate to Treat Patients With Acute Liver Failure/Severe Acute Liver Injury
This Phase 2a clinical study is designed to provide data on OCR-002 in patients with acute liver failure/acute liver injury (ALF/ALI) in regard to: safety and tolerability; metabolism of the compound to glutamine and…
- Trial name
- STOP-ALF (NCT01548690)
- Testing
- Ornithine Phenylacetate
- Where
- 11 sites in United States
- Volunteers
- 47 people
- Sponsor
- William Lee
Drug Induced Hepatotoxicity, Tuberculosis
Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage
Purpose of the study is to evaluate the safety and efficacy of different re-introduction regimens in anti-TB drug induced liver damage. There is no consensus how best to treat such patients who developed drug induced liver damage.
- Trial name
- NCT00405301
- Testing
- Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)
- Where
- 2 sites in India
- Volunteers
- 175 people
- Sponsor
- All India Institute of Medical Sciences
Drug-Induced Liver Injury
Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule.
This is a prospective registry study to surveil early liver injuries caused by Runzao Zhiyang Capsule (RZZY Capsule) through a non-intervention observational way.
- Trial name
- NCT03091218
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Drug-Induced Liver Injury, Musculoskeletal Diseases
Liver Enzyme Abnormalities and Risk Factors in Taking Herbal Medicine
Herb-induced liver injury is an important issue in musculoskeletal diseases where herbal medicine is most frequently used. The low prevalence of drug-induced liver injury (DILI) gives rise to the need for large-scale patient…
- Trial name
- NCT02299739
- Testing
- Herbal medicine, Acupuncture, Pharmacopuncture
- Where
- South Korea
- Volunteers
- 6,894 people
- Sponsor
- Jaseng Hospital of Korean Medicine
Drug-Induced Liver Injury
Surveillance for Early Liver Injuries Caused by Yangxue Shengfa Capsule.
This is a prospective registry study to surveil early liver injuries caused by Yangxue Shengfa Capsule (YXSF Capsule) through a non-intervention observational way.
- Trial name
- NCT03113838
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Beijing 302 Hospital
Hepatitis
The MARS® Albumin Dialysis System in Patients With Fulminant and Subfulminant Hepatic Failure
The purpose of this study is to improve the survival rate of those patients with acute fulminant hepatitis through treatment with the MARS® extra-corporal liver-purification system by: 1.
- Trial name
- NCT00224705
- Testing
- Molecular Adsorbent Recirculating System (MARS®)
- Where
- France
- Volunteers
- 110 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Drug Induced Liver Injury
Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury
The purpose of this study is to explore the efficacy and the safety of polyene phosphatidylcholine Injection in patients with acute drug-induced liver injury after 2-4 weeks of treatment.
- Trial name
- NCT04595916
- Testing
- Polyene phosphatidylcholine injection 930 mg QD, Magnesium Isoglycyrrhizinate injection 200 mg QD
- Where
- 9 sites in China
- Volunteers
- 73 people
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Tuberculosis Infection
Analysis of Liver Injury Risk Factors in a Multiethnic Population Treated With Antituberculosis Drugs
Tuberculosis (TB) is the world's second leading cause of death from a single infectious agent after COVID-19. In 2022, TB was estimated to have affected 10.6 million people, of whom 1.3 million died because of it, despite the…
- Trial name
- TUBILI (NCT06539455)
- Testing
- standard anti-TB treatment
- Where
- Italy
- Volunteers
- 127 people
- Sponsor
- Stefania Cheli
Brain Tumor, Central Nervous System Tumor
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy
RATIONALE: Sodium thiosulfate may reduce or prevent hearing loss in young patients receiving cisplatin for cancer. It is not yet known whether sodium thiosulfate is more effective than no additional treatment in preventing…
- Conditions
- Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00716976
- Testing
- sodium thiosulfate, examination
- Where
- 76 sites in United States, Australia and 1 more
- Volunteers
- 131 people
- Sponsor
- Children's Oncology Group
Colorectal Cancer, Liver Metastases
SAMe in Prevention of Oxaliplatin-associated Liver Injury
This is an open-label, phase II study that may provide evidence that taking S-adenosylmethionine (SAMe) supplementation prevents oxaliplatin, a type of chemotherapy drug, associated liver toxicity in patients with resectable…
- Conditions
- Colorectal Cancer, Liver Metastases, Liver Metastasis Colon Cancer, Liver Injury
- Trial name
- NCT06258525
- Testing
- Standard of care oxaliplatin-based chemotherapy, S-adenosylmethionine (SAMe) supplement, Surgery
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cedars-Sinai Medical Center
Non Alcoholic Fatty Liver, Hepatitis B
Combi-elastography Assessment of Chronic Liver Disease Multi-center Study
HITACH developed a new combi-elastography imaging technology combines shear wave imaging and strain imaging technology. In the study, not only the F index which is related to the stage of liver fibrosis can be obtained, but also…
- Conditions
- Non Alcoholic Fatty Liver, Hepatitis B, Drug-induced Liver Injury
- Trial name
- NCT04625166
- Where
- China
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Virus Disease
Collection of Liver Tissue for Virologic Studies
This study will examine liver tissue to investigate the role of viral infections in fulminant hepatitis, liver failure, and profound bone marrow failure.
- Trial name
- NCT00005936
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Tuberculosis Infection, Tuberculosis Infection, Latent
Isoniazid-Related Hepatotoxicity in Clinical Practice: Incidence and Predictors
The objective of this observational study is to determine how frequently isoniazid (INH) causes liver injury (hepatotoxicity) in adults treated for tuberculosis (TB) or latent tuberculosis infection (LTBI) and to understand which…
- Trial name
- INH-DILI (NCT07472348)
- Testing
- Standard isoniazid-based TB/LTBI therapy
- Where
- Italy
- Volunteers
- 220 people
- Sponsor
- ASST Fatebenefratelli Sacco
Tuberculosis, Drug Induced Liver Injury
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
To determine the efficacy of NAC to prevent clinically significant anti-TB drugs induced liver injury (AT-DILI).
- Conditions
- Tuberculosis, Drug Induced Liver Injury, Hepatitis
- Trial name
- NCT05738681
- Testing
- N acetyl cysteine
- Where
- Thailand
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Drug-induced Liver Injury
Correlative Cohort Study on the Clinical Features and Prognosis of Drug-induced Liver Injury
This was a retrospective study of a clinical observational cohort. The patients were admitted and definitely diagnosed by liver biopsy as drug-induced liver injury from September 2014 to September 2019, in the Second Department…
- Trial name
- NCT04302506
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Beijing Ditan Hospital
Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease
Ultrasound Method to Measure Fibrosis of the Liver in Children
HYPOTHESIS: The investigators hypothesize that sonoelastography (SE) provide accurate quantitative measurements that can be used to stage liver fibrosis in pediatric patients with chronic liver disease.
- Conditions
- Chronic Liver Disease, Non-Alcoholic Fatty Liver Disease, HCV Coinfection, HBV
- Trial name
- NCT02086708
- Testing
- Shear Wave sonoelastography
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Chemical and Drug Induced Liver Injury
Hepatotoxicity of Antituberculosis Therapy (HAT) Study
Drug-induced liver injury (DILI) is a common side effect in antituberculosis therapy, which interuputs the treatment of TB and leads to a higher proportion of Multidrug-Resistence TB(MDR-TB).The study primalily aims to observe…
- Trial name
- HAT (NCT04159441)
- Testing
- None intervetion
- Volunteers
- 5,000 people
- Sponsor
- Huashan Hospital
Liver Injury, Drug-Induced
Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury
The most common toxicity of TP (docetaxel and cisplatin) chemotherapy is chemotherapy-induced liver injury. However, patients don't always experience same chemotherapy-induced liver injury for the same drugs.
- Trial name
- NCT03069820
- Testing
- docetaxel and cisplatin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital of Nanchang University
Drug-induced Liver Injury
Impact of Silymarin Dosages to Decrease Drug-induced Elevated Liver Enzymes Compared to Placebo
In this clinical study silymarin will be administered in different dosages and compared to placebo in order to address if the liver protecting features of silymarin, measured by changes of liver enzyme concentration, can be…
- Trial name
- SILVER (NCT05144217)
- Testing
- 2x 140 mg per day, 3x 280 mg per day, 1x 1120 mg
- Where
- 2 sites in Germany
- Volunteers
- 19 people
- Sponsor
- Prof. Dr. Frank Behrens